chi2=4.01, df=1, p=.045, odds ratio OR=2.31, 95% confidence interval CI=1.00-5.31
Adjusted OR<=>95% CI Interaction model Adjusted OR<=>95% CI, eta2

COMPLICATED GRIEF SYMPTOMS IN ANXIETY DISORDERS: PREVALENCE AND ASSOCIATED IMPAIRMENT

COMPLICATED GRIEF AND BEREAVEMENT IN YOUNG ADULTS FOLLOWING CLOSE FRIEND AND SIBLING LOSS

friend N=66 M SD Sibling M SD Nonbereaved N=34
N=27 experienced mild severe depression compared-18%
N=6 who experienced no loss, chi2(1)=4.07, p=.047

ROLE OF ALLELIC VARIANTS OF FK506-BINDING PROTEIN 51 (FKBP5) GENE IN THE DEVELOPMENT OF ANXIETY DISORDERS

FAMILY AGGREGATION AND RISK FACTORS OF OBSESSIVE-COMPULSIVE DISORDERS IN A NATIONWIDE THREE-GENERATION STUDY

N=6055 controls without any psychiatric diagnosis before age 18

SEX DIFFERENCES IN DNA METHYLATION MAY CONTRIBUTE TO RISK OF PTSD AND DEPRESSION: A REVIEW OF EXISTING EVIDENCE

CORTICOTROPIN RELEASING HORMONE RECEPTOR 2 (CRHR-2) GENE IS ASSOCIATED WITH DECREASED RISK AND SEVERITY OF POSTTRAUMATIC STRESS DISORDER IN WOMEN

uncorrected ps=.0004 and.0005, odds ratios=.60 and.58
uncorrected ps=.0003 and.0002, odds ratios=.41 and.35
uncorrected ps=.001, both odds ratios=.48
Table 2, model C1 unstandardized b=-1.96, p=.01

PATIENT SELF-ASSESSMENT FACTORS PREDICTIVE OF PERSISTENT DEPRESSIVE SYMPTOMS 6 MONTHS AFTER ENROLLMENT IN COLLABORATIVE CARE MANAGEMENT

CBT COMPETENCE IN NOVICE THERAPISTS IMPROVES ANXIETY OUTCOMES

un nested hierarchical linear regression

PERILOSS DISSOCIATION, SYMPTOM SEVERITY, AND TREATMENT RESPONSE IN COMPLICATED GRIEF

true'-5='extremely true.' Total scores range=10-50

REPORTS OF DRINKING TO SELF-MEDICATE ANXIETY SYMPTOMS: LONGITUDINAL ASSESSMENT FOR SUBGROUPS OF INDIVIDUALS WITH ALCOHOL DEPENDENCE

ratio AOR=5.71, 95% confidence interval CI=3.56-9.18, p<.001

PILOT STUDY OF THE CLINICAL AND COGNITIVE EFFECTS OF HIGH-FREQUENCY MAGNETIC SEIZURE THERAPY IN MAJOR DEPRESSIVE DISORDER

THE EFFICACY OF A TOPICAL SIALOGOGUE SPRAY CONTAINING 1% MALIC ACID IN PATIENTS WITH ANTIDEPRESSANT-INDUCED DRY MOUTH: A DOUBLE-BLIND, RANDOMIZED CLINICAL TRIAL